Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Solid Tumor, Adult 1Sarcoma, Synovial 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lymphatic Metastasis 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Gliosarcoma 1Glioblastoma 1Dermatofibrosarcoma 1

Interventions

Cyclophosphamide 5fludarabine 3Specimen Handling 2Magnetic Resonance Spectroscopy 2Doxorubicin 2peposertib 1pembrolizumab 1pasireotide 1olaparib 1lutetium Lu 177 dotatate 1liposomal doxorubicin 1fludarabine phosphate 1anlotinib 1aldesleukin 1Zoledronic Acid 1X-Rays 1Tablets 1Rosuvastatin Calcium 1Quality of Life 1Phantoms, Imaging 1Midazolam 1Leukapheresis 1Interleukin-2 1Injections 1Immunotherapy, Adoptive 1Immune Checkpoint Inhibitors 1Ifosfamide 1Digoxin 1Dacarbazine 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Sarcoma, Synovial × peposertib × Clear all
NCT05711615 2026-05-15

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

National Cancer Institute (NCI)

Phase 1 Recruiting
30 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡